Characterization of the P4 promoter region of the human insulin-like growth factor II gene  by Hyun, Sang Won et al.
Volume 332, number 1,2,153-158 FEBS 13091 
0 1993 Federation of European Biochemical Societies ~145793/93~~.~ 
October 1993 
Characterization of the P4 promoter region of the human insulin-like 
growth factor II gene 
Sang Won Hyun”, Seong-Jin Kim’, Keunchil Park”, Hyune MO Rhob, Young Ik Leea* 
“The ~boratory of ~ole~lar Genetics, Genetic ~~g~e~~g research artiste, ~aejo~, KIST, Daeduk Science Town* lkjon, 
South Korea 
‘~epart~nt of Molecular Biology, Seoul National University, Seoul, South Korea 
“The Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, ML, 20892, USA 
Received 30 June 1993; revised version received 23 August 1993 
The Truman insulin-like growth factor II (IGF-II) gene contains four promoters (Pl, P2, P3 and P4). In order to determine the mechanism by which 
the P4 promoter is controlled, the human IGF-II P4 promoter was analyzed in cell lines. DNA sequence analysis of the human IGF-II P4 promoter 
gene showed that the P4 promoter region contains a TATA-like sequence and several G + C rich regions which are essential for transcription. 
Analysis of the transcription initiation site by Sl nuclease mapping revealed two transcription start sites; both are located immediately behind 
TATA-like sequence. To determine the location of sites that may be important for the function of the human IGF-II P4 promoter, we constructed 
chime% genes of the human IGF-II P4 promoter fused to the coding region for chIoramphenico1 acetyltransferase (CAT). These constructs were 
transfected into HepG2, PLCYPRFB, G401 and A549 cells, and were exam&d for CAT activity. All transfected cells showed a similar profile of 
CAT activity. Sequences responsible for putative enhancer and silencer egions were identified and the 5 flanking sequences of the human IGF-II 
P4 promoter contain negative regulatory regions (-213 to -174). The 53-base pair fragment located between 111 and 59 base pairs upstream of 
the start site contains positive regulatory activity. Gel mobility shift assay showed that Spl and another proteins might be involved in positive 
regulation of the human IGF-II P4 promoter. 
IGF-II P4 promotor; Positive regulatory element; Negative regulatory element; Spl binding sequence; Egr-1 element 
1. INTRODUCTION 
Insulin-like growth factor II (IGF-II) is a fetal growth 
factor which is known to act on fetal development and 
differentiation [l]. Although IGF-II is s~ctu~y re- 
lated to insulin and IGF-I, its physiological function is 
not fully understood. The genomic structure of the IGF- 
II gene spans about 35 kb, which includes nine exons 
and four promoters [2-51. Structural analysis of rat and 
human IGF-II cDNA clones and their genes reveal the 
presence of alternatively used leader exons which are 
responsible for the generation of multiple transcripts, in 
which they provide S-untranslated regions that are var- 
iable in length and sequence. Transcription of the 
human IGF-II gene yields 6 kinds of mRNA species 
which are expressed in a tissue-specific and develop 
ment-s~~ manner. In human adult liver tissue, a 5.3 
kb mRNA species is dominant, while two other species 
of mRNAs, 6.0 and 4.8 kb, are dominant in many fetal 
liver and non-hepatic tissues. Each of these IGF-II 
mRNAs is expressed under the control of 4 different 
promoters [6]. High levels of IGF-II mRNAs have been 
reported in many tumors and tumor cell lines including 
Wilms’ tumors and rhabdomyosarcomas [A, whose 
expression is owed to promoters 3 and 4 preceding 
exons 5 and 6, respectively, which induces the expres- 
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sion in fetal liver. Also in primary liver cancers and 
some cirrhotic tissues surrounding liver cancer, fetal 
types of IGF-II transcripts are expressed [8]. 
To obtain more insight in the mechanisms involved 
in the regulation of the IGF-II gene expression, the 
IGF-II promoters have been characterized [5,9]. Pro- 
moters P3 and P4 are expressed in all fetal and in non- 
hepatic adult tissues, whereas in adult liver, the P2, P3 
and P4 promoters are completely shut off and promoter 
Pl is activated [5]. P3 promoter is well characterized. 
This promoter contains the TATA box and four bind- 
ing sites for nuclear proteins [9]. Recently, it has been 
reported that the P3 promoter contains three binding 
sites for the transcription factor Egr-1 (early growth 
response element}, suggesting that these motifs are im- 
portant for the basal expression of the human IGF-II 
gene under the control of the P3 promoter [lO,l 11. Stud- 
ies on the human P4 promoter and its corresponding rat 
promoter (P3) of the IGF-II gene have recently been 
reported [12,13]. Among the findings was the identifi- 
cation of a distinct promoter region containing multiple 
Spl-binding sequences and a TATA-like sequence. 
Even though human IGF-II P4 promoter was examined 
[ 131, the specific elements regulating the human P4 pro- 
moter were not characterized. 
In this paper we report the characterization of the P4 
promoter of the human IGF-II gene which regulates the 
transcription of the 4.8 kb mRNA in fetal liver. We have 
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undertaken this study to increase our understanding of 
the important conserved regulatory elements critical for 
expression of human IGF-II under the control of the P4 
promoter and to extend our promoter studies to differ- 
ent biological systems. 
2. MATERIALS AND METHODS 
2.1. Nucleotide sequence determination and plasmid construction 
The fourth (P4) promoter of the human IGF II gene-CAT chime& 
construct was generated as follows: plasmid pHIGF 11-14-6 was di- 
gested with NruI and BstEII (-411 to +124). After the ends were tilled 
in, the resulting fragment was inserted into SmaI site of the multiple 
cloning site of the pGEM-SVOCAT [22]. To sequence the NruIIBstEII 
(-411 to +124) fragment, a 540 bp insert was obtained from pIG0 by 
digesting the plasmid with HindIIIl&nI restriction enzymes which are 
present in the multiple cloning site, and subcloned into the vectors 
Ml3 mp 18 and 19. The nucleotide sequence was determined by the 
dideoxy chain termination method. The deletion mutant series of the 
P4 promoter of the human IGF-II gene was constructed by PCR 
amplification using oligonucleotides designed to generate nds with 
Hi&II and XbaI restriction sites. The PCR product was then cloned 
into pGEM4-SVGCAT which was cut with the same enzymes. The 
constructed plasmids were purified in two sequential CsCl centrifuga- 
tion steps for maximum activity. 
2.2. Cell culture, transfection and CAT assays 
Human hepatoma cells, PLC/PRF/S and HepG2, were grown in 
minimal essential medium supplemented with 10% fetal bovine serum. 
Human lung adenocarcinoma (A549) cells were grown in Dulbecco’s 
modified Eagle’s medium with high glucose supplemented with 5% 
fetal bovine serum. Wilm’s tumor (G401) cells were grown in McCoy’s 
5a medium with 10% fetal bovine serum. 
Transfections were carried out by the calcium phosphate co-precip- 
itation method [23]. Cells were transfected with 10 pug of plasmids. 
Briefly, the cells were incubated with the plasmid DNA for overnight 
and then exposed to 15% (v/v) glycerol in 20 mM HEPES buffer for 
2 min. After glycerol shock, the cells were further incubated for 48 h 
in complete medium. The cells were then harvested and extracts were 
assayed for CAT activity according to the method of Gotman et al. 
[24]. CAT enzyme activity was normalized for transfection efficiency 
by co-transfection of 2.0 pug of the /Qgalatosidase expression plasmid 
pCHll0 and measuring the /I-galactosidase activity of the individual 
extracts of the transfected cells. 
2.3. Nuclease protection assay 
Total RNA was prepared from PLC/PRF/S cells transfected tran- 
siently with the plasmid plG5 according to the method of 
Chomczynski and Sac&i [25]. The plasmid pIG5 was linearized with 
XbaI, dephosphorylated, end-labeled with [y-“P]ATP by T4 polynu- 
cleotide kinase, and digested with Hi&II. The resulting fragment 
(- 111 to + 129) was gel-purified and used as a probe. Total RNA (60 
pg) was co-precipitated in ethanol with 1 x lo6 c.p.m. of an end- 
labeled DNA probe representing the HindIII-XbaI fragment of pIG5 
(-111 to + 129) (see Fig. 3). Hybridization was performed by dissolv- 
ing the precipitate in 40~1 of hybridization buffer (80% formaldehyde, 
20 mM Tris, pH 7.4, 0.4 M NaCl, 1 mM EDTA), heating for 15 mm 
at 75°C and incubating for 16 hat 58°C. The DNA-RNA hybrid was 
diluted into 360~1 of Sl nuclease buffer (0.01 M NaCl, 0.1 mM ZnS04, 
and 2 mM sodium acetate, pH 4.5) containing 2 pg of denatured 
salmon sperm DNA and 150 units of Sl nuclease, and incubated at 
37°C for 1 h. The protected fragments were recovered by ethanol 
precipitation, denatured, and analyzed on a 6% polyacrylamide gel. 
2.4. DNase I footprinting 
A DNA probe was prepared from the plasmid plG3 (Fig. 3) contain- 
ing the promoter fragment from - 174 to + 129 cloned into the Hind111 
and XbaI site of the polylinker region. This fragment was labeled with 
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[y-‘*P]ATP at the XbaI linker (+129) using T4 polynuclease kinase and 
recut at the Hind111 site in the vector. The resulting 303 bp fragment 
was purified from the 6% native polyacrylamide gel. Nuclear extracts 
were prepared from PLC/PRF/S cells as described by Osbom et al. 
[26]. DNase I foot-printing was performed by mixing 5Opg of nuclear 
extracts and 0.5-2 ng of pm-i&d DNA fragment per reaction accord- 
ing to the method of Angel et al. [27]. 
2.5. Gel retardation assay 
Gel mobility shift assays were carried out as described [20] with 
some modifications. The constructed plasmids plG5, plG5-1, plG5-2, 
plG5-3 and plG6 were digested with ZfindIII, end-labeled with 32P and 
then digested with SmaI. The 32P-labeled promoter fragments were gel 
puritied and each incubated with PLCIPRFIS and A549 cell extracts. 
The DNA-protein complexes were analyzed on polyacrylamide gels’. 
Electrophoresis of DNA-protein complexes was carried out at 4’C in 
5% polyacrylamide gels in 0.5 x TBE. 
3. RESULTS 
3.1. Transcription initiation sites and analysis of the P4 
promoter egion of the human IGF-II gene 
Using Hind111 and QnI restriction sites in plG0 
(Fig. 4), the 540 bp fragment containing the human 
IGF-II P4 promoter was subcloned into the vectors 
Ml 3 mp18 and 19, and its sequence was determined 
(Fig. 1). The sequence includes 411 nucleotides up- 
stream and 129 nucleotides downstream of the exon 6 
of the human IGF-II gene. The deletion mutant series 
of the human IGF-II P4 promoter gene were con- 
structed by PCR amplification using oligonucleotides 
designed to generate ends with Hind111 and X&a1 re- 
striction sites. The PCR product was then cloned into 
pGEMCSVOCAT which was cut with the same en- 
zymes. The transcriptional start sites were located by Sl 
nuclease protection analysis using a 240-bp HindIIV 
_%%a1 fragment (plG5) extending from the nucleotide 
-111 to the nucleotide +129 (see Fig. 1). This fragment 
was end-labeled at the 5’ terminus of the XbaI site prior 
to digestion with Hind111 and subsequently isolated 
from the agarose gels. Using this probe we were able to 
observe two Sl nuclease-resistant fragments after hy- 
bridization with PLC/PRF/S mRNA transfected with 
plG3 plasmid (Fig. 2). Sl analysis showed that tran- 
scriptional start sites were located just behind the 
TATA-like sequence and were only two nucleotides 
apart. Their locations are 20 or 29 bp upstream com- 
pared with rat IGF-II exon 3 which is equivalent to 
human IGF-II exon 6 [14,15]. 
DNase I footprinting assay showed three protected 
regions when the PLC/PRF/S nuclear extracts were 
mixed with labeled plG3 fragment (- 174 to +129, Fig. 
3). Protected regions a and b are G + C rich, suggesting 
that Spl may bind to these regions. The third protected 
‘The human Spl protein was obtained from Promega. The Spl com- 
petitors consisted of the 22 bp fragments; 5’-A’ITCGAT CGGGG- 
CGGGGCGAGCJ’. The API, AP2 and CREB competitor frag- 
ments were 5’-CGCTTGATGAGTCAGCCGGAA-3’, S- GATCG- 
AACTGACCGCCCGCGGCCCGT-3’, and 5’-AGAGAITGCCTG- 
ACGTCAGAGAGCTAG3’, respectively. 
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Fig. 1. Schematic presentation of the human IGF-II gene region and 
nucleotide sequence and restriction map of the S-flanking region (P4 
promoter) of exon 6. Exons are represented by boxes and coding 
regions of the gene are shown by black boxes. The 540 bp NruI-BstEII 
fragment which contains the blGF-II P4 promoter region was sub- 
cloned into pGEM4-SVO CAT, and the insert was cloned into the 
Ml3 mp18 and 19 vectors. The sequence was determined by the dide- 
oxy chain termination method. Several potential transcription factor 
binding sites were analyzed through computer-aided search. Tran- 
scription initiation sites were determined by Sl nuclease analysis. The 
S-ends of serially deleted promoter mutants are indicated as numbers 
0 to 9. Potential API [16], Spl[27] and C&BP binding sites are shown 
by broken underlining, open boxes and thick solid underlining, respec- 
tively. Closed circles and the closed triangle indicate the transcription 
start sites and TATA box, respectively. 
region c is the TATA-like sequence and upstream se- 
quences, which might be covered by a TATA box-bind- 
ing protein. 
Examination of the sequences howed several poten- 
tial transcriptional factor binding sequences, including 
ClEBP at -241, APl at +3, and Spl at -84, -54 and 
-32 (Fig. 1). However, our data showed that C&BP 
and API binding sequences were not likely to play a 
significant role in the transcriptional regulation of the 
human IGF-II P4 promoter (Fig. 5, 7). 
3.2. Putative negative and positive regulatory regions in 
the P4 promoter of the human IGF-II gene 
To find out the regulatory elements of the P4 pro- 
moter of the human IGF-II gene, various portions of 
the promoter region deleted from the S-end were fused 
to the coding region of the bacterial chloramphenicol 
acetyltransferase (CAT) gene in the pGEM4-SVOCAT 
vector (Fig. 4). These constructs were transfected into 
HepG2, PLCYPRFIS, G401 and A549 cells. Fig. 5 shows 
the basal CAT activity in the several transfeeted cell 
lines. Deletion of the fragment from -213 to -174 in- 
creases the CAT activity in all cell lines except A549, 
while deletions from -111 to -59 sharply decreases 
CAT activity in all cell lines tested. This result suggests 
that the sequence from -213 to -174 contains a nega- 
tive regulatory element and the sequence from -111 to 
-59 contains a positive regulatory element. In A-549 
cells, CAT activity was increased when the region be- 
tween nucleotide -174 and nucleotide -127 is deleted. 
Deletion of the fragment from -58 to -37 slightly in- 
creases CAT activity while further deletion to -22 
slightly decreases CAT activity in all cell lines tested 
except A-549 cells. Taken together, these data suggest 
that the S’-flanking sequences of the fourth promoter of 
the human IGF-II gene contain two negative regulatory 
regions (-213 to - 174 and - 174 to - 127) which repress 
the transcription unit very efficiently, depending on the 
cell types. 
3.3. Identzjkation of nucleoproteins bound to the P4pro- 
moter region of the human IGF-II gene 
Gel mobility shift assays were carried out with 32P- 
labeled P4 promoter fragments to identify the proteins 
which might be involved in the transcriptional regula- 
tion of the human IGF-II gene. Since deletion analysis 
showed that the sequences between -111 and -59 were 
responsible for positive regulation, we attempted to 
z=-= 
Fig. 2. Nuclease protection assay. PLCIPRFIS cell mRNA was ana- 
lyzed by Sl nuclease protection assay with the ~~dIII-~QI fragment 
labeled at the 5’ end of the fia1 site as described in Section 2. Lane 
A, total RNA from PLCYPRFIS plus probe, protected fragments of 
127 and 129 bp are shown; lane B, aliquot of probe, Sl protected 
fragments were analyzed by electrophoresis on a 5% polyacrylamide 
sequencing el containing 8 M urea. The size of the protected fragment 
was determined by co-electrophoresis of the sequencing samples of the 
human IGF-II gene fragment. Lane M, molecular weight marker 
(pBR322 DNA + &@I). 
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242- 
217 - 
al- 
K 
-127 -100 
CAGGAGA GAAGAGACTG GCTGGGAGGA GGGAGAGGGC GGGAGCAAAG 
-80 
GCGCGGGGGA GTGGTCAGCA 
-30 
GGGCTGGGAG GAGTCGGCTC 
Ml234 
B 
b 
AP2 and CREB oligonucleotide did not show any effect 
to the bands at all (Fig. 7A, lanes 5, 6 and 7). And 
purified Spl protein was used for a gel mobility shift 
assay using the plG5 fragment (- 111 to -31) as probe 
(Fig. 7B). The consensus Spl oligonucleotide (lane 2) 
was able to compete nearly all of the binding of Spl to 
the P4 promoter fragment of the human IGF-II gene. 
c 4. DISCUSSION 
a 
-50 
GGGAGAGGGG TGGGGGGTAG GGTGGAGCCC 
b 
-1 
ACACATAAAA GCTGAGGCAC TGACCAGCCT 
C 
Fig. 3. Identification of protein binding region in the P4 promoter by 
DNase I footprinting. A DNA fragment containing 303 bp of the P4 
promoter region from position -174 (HindIII) to +129 (XbaI) was 
prepared as probe and end-labeled with 32P at the .X%oI site. The probe 
was incubated with 25 pg of bovine serum albumin (lane A), or 5 (lane 
B), 10 (lane C) or 15 ,ul (lane D) of PLC/PRF/S nuclear extracts. Three 
protected regions are designated as a, b and c. Lane M, molecular 
weight marker (pBR322 DNA + &PI). 
characterize the proteins binding to these regions. For 
this purpose, five fragments were prepared from the 
plasmids plG5, plG5-1, plG5-2, plG5-3 and plG6 (- 111 
to -31, -102 to -31, -87 to -31, -81 to -31 and -72 
to -31, respectively) by digesting each plasmid with 
Hind111 and SmaI restriction enzymes, and end-labeled 
as described in Section 2. These probes were separately 
incubated with nuclear extracts isolated from A549 
cells, and electrophoresed on native polyacrylamide 
gels. There were several bands showing protein bind- 
ings, which disappeared in the presence of lOO-fold 
molar excess of unlabeled fragments (Fig. 6 and unpub- 
lished data). Three major retarded bands were desig- 
nated as a, b, and c. Complexes a and c disappeared 
when the deletion reached to -72. To confirm whether 
these binding proteins are related to the known DNA 
binding proteins, we carried out competition assays 
using oligonucleotides of Spl, API, AP2, and CREB 
binding consensus equences in gel mobility shift assays. 
When a lOO-fold molar excess of Spl oligonucleotide 
was added, two major bands (a and b) disappeared, but 
not two minor bands (c and d), suggesting that the top 
two bands are the specific bands representing Spl bind- 
ing (Fig. 7A, lanes 3 and 4). This result shows that Spl 
and another protein are involved in the positive tran- 
scriptional regulation of the P4 promoter. On the other 
hand, addition of a l~fold molar excess of each API, 
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In both human and rat, all of the mRNA transcripts 
of the IGF-II gene exhibit tissue- and development- 
specific regulation, and transcription of each transcript 
is controlled by separate promoters. The P4 promoter 
of the human IGF-II gene corresponds to the P3 pro- 
moter of the rat IGF-II gene, and they show nearly 75% 
homology in nucleotide sequence [14,15]. The P4 pro- 
moter regulates the transcription of the 4.8 kb mRNA 
at the fetal stage in the liver. In this report, we have 
characterized several regulatory elements of the P4 pro- 
moter of the human IGF-II gene and regulatory pro- 
teins related to it. 
Although the human IGF-II P4 promoter and its 
corresponding rat promoter (P3) appear well conserved 
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Fig. 4. Structure of P4 promoter of hIGF-II gene-CAT chimeric genes. 
The construct containing upstream sequences up to nucleotide -411 
of exon 6 of the human IGF-II gene was used to construct deletion 
mutant plasmids, plG0 to plG9. The solid bars represent various 
portions of the P4 promoter region produced by PCR amplification. 
The lirst trmscription initiation site identified by Sl mapping is indi- 
cated as +l. The column on the right shows relative CAT enzyme 
activity obtained in several experiments with each plasmid in PIE/ 
PRFl5 cells. Transfection efficiency was normalized as described in 
Section 2. 
EWE Fvws 
Fii 5. Expressi#n of 5’~~etion mutants of htmlan IGF IT P4 pro- 
moter-CAT fusion gems+. ‘Be ceBs were transiently transf~ted wit& 
the pIG DNA series irito HepG2, PLCIPRFIS, G4EH and AS49 cells= 
The positions of the S-e&s of deletion mutants are described inFigs. 
1 and 4. J%e cells examined here exhibit sir&u protiles of transkp- 
tional activities. Transfectkm eRicknq was itormalked as described 
in Section 2. Each. experiment was repeated at ieast hree times. 
in sequence and in general structure, the transcriptional 
initiation site in the human IGF-II gene under the con- 
trol of the P4 promoter was identified 2 nueleotides 
upstream relative to that of the rat start site [la]. Our 
Sl analysis of the total RNA prepared from the FLC! 
PRFfS eells transfected with the plasmid plG3 indicated 
that the transcriptional start site is aIso different from 
the piously reported one fl3]. This may be due to the 
fact that we have prepared the total RNA from the 
PLCYPRF15 cells transfected with the plasmid plG3. 
We examined the basal expression of the P4 promoter 
deletion mutants-CAT chimeric constructs in several 
cell lines. We identified that the human IGF-II P4 pro- 
moter contains both negative and positive regulatory 
elements. Deletion of the negative regulatory region 
(-213 to -174) resulted in a increase of the trisect 
tional activity of the promoter, while removal of the 
putative positive regnlatory region f-111 to -591 
sharply decreased the t~~~~o~~ activity of the 
humrm IGF-II P4 promoter (Fig. 5). The region be- 
tween -111 and -59 was also positiveIy regulated by the 
protein phosphatase inhibitor okadaic acid, a non- 
TPA-type tumor promoter (manuscript submitted). The 
more detailed analysis revealed that the E&r-l element, 
located between ucleotide -78 and -70, is responsible 
for the induction of P4 promoter activity by okadaic 
acid. Since the deletion from -111 to -59 .sharPly de- 
creases CAT ac~~ty~ it is likely that the Egr-1 element 
is the major ~an~~Ftion factor responsible for the 
basal exmession of human IGF-II under the control of 
the P4 promoter. These results uggests that for maxi- 
mum expression of the promoter, atleast 111 base pairs 
upstream from the transcription initiation site are re- 
quired. 
Analysis of the human IGF-II P4 promoter has 
shown several G + C rich regions which are essential for 
transcription [l&-20], In particular, there are three pos- 
sible Spl binding sequences within 100 bp upst~~ 
from the t~s~~tio~ start site, which are clustered in 
the positive regulatory region. Incubation of the plG5 
fm~e~t with A549 nuclear extracts in the presence of 
Spl as speci& competitor resulted in the ~sap~aran~ 
of the bands a and b (Fig. 7A), which suggests hat Spl 
binds to the P4 promoter and is involved in the tran- 
scription of human IGF-II gene. 
Sequence analysis also revealed one possible API 
binding sequence ioeated at just behind the transcrip 
tion start site. Wowever, the DNase I protection assay 
did not show any protein binding to this region (Fig. 3) 
and gel mobility shift assay with AH oligonncl~otide as
competitor also did not show any interference to the 
DNA-protein int~rac~on (Fig. 7A). The binding se- 
quence of another Imtative ~an~~tio~ factor, C&BP, 
is located at -241. CfEBP is known to function as a 
mnnnm 
Competiiar - + - f - + - + - + 
a- 
b- 
G- 
7 2 3 4 5 6 7 8 9 10 
Fig. 6. MeWification of specific binding of proteins to the human IGF 
II P4 promoter region. Five DNA fragments from plGS (-111 to -31), 
plG5-1 (-102 to -31)s PlGS-2 (-87 to -31), plGS-3 (-81 to -31) and 
plG4 (-72 to -31) were each end-labeled at the HindIII site and 
purified for probes. Each probe was incubated with PLUPIWS cell 
extracts in the presence (+) of absence (-) of specific ompetitor, The 
bands resulting from the specific binding of proteins to PIGS ~a~ent 
are shown. In all cases, the bands disappeared when ~~-foid molar 
excess of~rn~~to~ were added. 
d- 
b- 
d- 
Fig. 7.l2etwtio~ af w&lar fa&ofs that bind to %e ~~~ EGF-Xl W 
promotei-. (a) The plOS fragment (-I II to -31) was ~~~~t~ with 
a nuclear extracts fmm AS49 cells in the presence or abs@xzm of a 
specific competitor and the DNA-protein complexes were ge:1 alectrom 
phoresed. Two major retarded bands are visualized (lane I), Binding 
was competed with IM)-fold molar excess of unlabeled ~10.5 fragment 
(lane 2) and syntbatic ~il~onucleotide corresponding to tb8 Spl bind- 
ing consensus equences (lane 3 and 41, respectively. (b) Spl binds 
diractly to the W promoter of the human IGF-XI gene?, ~~~~~ rea- 
tions witb 15 q&l pure Spf (Fromega) were done as described ix~ 
Section 2. 
The data p~~~~~~~d here indicate that the ~~~~r~ 
structure of the Ermnan IGF-II P4 promoter is similar 
to the human IGF-II P3 promoter [I 11. Transcription 
factors suggested to play a role in the regulation of” both 
P3 and P4 promotars include the tr~scriptio~ factors 
Spl and Egr-1 s l?urther charaete~tion of the role; of 
these tr~~~pt~~~ factors in the regulation of EGF-II 
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